The Cyclooxygenase 2 inhibitor etoricoxib as adjunctive therapy in tuberculosis impairs macrophage control of mycobacterial growth.
Kristin G NoreClaire LouetMarit BuggeAlexandre GidonMarthe Jøntvedt JørgensenSynne JenumAnne Ma Dyrhol-RiiseKristian TonbyTrude Helen FloPublished in: The Journal of infectious diseases (2023)
Our data suggest potential unfavorable effects with impaired macrophage capacity to control mycobacterial growth in tuberculosis patients receiving COX-2i treatment. Larger clinical trials are required to analyze the safety of COX-2i as HDT in patients with tuberculosis.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- clinical trial
- hiv aids
- adipose tissue
- electronic health record
- stem cells
- big data
- combination therapy
- climate change
- risk assessment
- deep learning
- human health
- study protocol
- hepatitis c virus
- antiretroviral therapy
- replacement therapy
- data analysis
- phase iii
- drug induced